Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Urol Oncol. 2022 Feb;40(2):56.e9-56.e15. doi: 10.1016/j.urolonc.2021.05.003. Epub 2021 Jun 8.
This study aimed to evaluate how health-related quality of life (HRQOL) is related to repeat protocol biopsy compliance.
We conducted a retrospective analysis using data from a prospective cohort in the Prostate Cancer Research International: Active Surveillance (PRIAS)-JAPAN study between January 2010 and August 2019. We used the Short Form 8 Health Survey (SF-8), as patient-reported outcomes, to assess HRQOL at AS enrollment and the first year of the protocol. The physical component summary (PCS) and mental component summary (MCS) were calculated from SF-8 questionnaires. The primary outcome was the evaluation of the association of HRQOL at enrollment on the first repeat biopsy compliance. The secondary outcome was the comparison of SF-8 scores during AS, stratified by repeat protocol biopsy compliance.
Of 805 patients who proceeded to the first year of the protocol, the non-compliance rate was 15% (121 patients). In the adjusted model, lower MCS at enrollment was significantly associated with the first repeat protocol biopsy non-compliance (odds ratio [OR], 2.134; 95% confidence interval [CI], 1.031-4.42; P = 0.041) but not in lower PCS (OR, 0.667; 95% CI, 0.294-1.514; P = 0.333). All subscales of SF-8 were lower in the non-compliance group than in the compliance group at any point. MCS in the non-compliance group improved over time from the time of AS enrollment (2.34 increased, P = 0.152).
Our data suggest that lower MCS at AS enrollment using patient-reported outcomes was negatively associated with the first repeat protocol biopsy compliance. Our study may support the availability of a simple questionnaire to extract non-compliance.
本研究旨在评估健康相关生活质量(HRQOL)与重复方案活检依从性的关系。
我们对 2010 年 1 月至 2019 年 8 月期间前列腺癌研究国际:主动监测(PRIAS)-JAPAN 研究的前瞻性队列数据进行了回顾性分析。我们使用患者报告的结局短表 8 健康调查(SF-8)来评估 AS 入组时和方案第一年的 HRQOL。SF-8 问卷计算了生理成分综合评分(PCS)和心理成分综合评分(MCS)。主要结局是评估 HRQOL 入组时对首次重复活检依从性的影响。次要结局是比较 AS 期间的 SF-8 评分,按重复方案活检依从性分层。
在 805 例进入方案第一年的患者中,不依从率为 15%(121 例)。在调整后的模型中,入组时 MCS 较低与首次重复方案活检不依从显著相关(比值比 [OR],2.134;95%置信区间 [CI],1.031-4.42;P=0.041),但 PCS 较低与首次重复方案活检不依从不相关(OR,0.667;95% CI,0.294-1.514;P=0.333)。任何时间点,SF-8 的所有子量表在不依从组均低于依从组。从 AS 入组开始,不依从组的 MCS 随时间推移而改善(2.34 增加,P=0.152)。
我们的数据表明,AS 入组时使用患者报告结局的 MCS 较低与首次重复方案活检依从性呈负相关。我们的研究可能支持使用简单的问卷来提取不依从。